Business Wire

Pudgy Penguins and Mythical Games Partner to Create AAA Mobile Video Game

Share

Pudgy Penguins, the brand development company behind the series of globally recognized Pudgy Penguins characters, and next-generation gaming technology studio Mythical Games today announced a partnership to create a unique web3-enabled mobile video game. The partnership unites the creators of the globally recognized Pudgy Penguins characters and the gaming studio behind two of the most successful blockchain games ever, NFL Rivals and Blankos Block Party.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530595937/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Details of the forthcoming game developed in conjunction with Mythical Games were announced at Consensus 2024. The upcoming mobile game will be an immersive video game drawing upon the lore and humor that have made Pudgy Penguins so beloved, coupled with AAA quality, playability, and accessibility synonymous with Mythical Games' title NFL Rivals. The new game is scheduled to launch on the Mythical platform in 2025, home to NFL Rivals, with over 5 million players, and the Mythos Chain (MYTH), with over one million active wallets.

“Web3 in gaming is evolving quickly, but one thing that hasn’t changed is the need for games to be powered by strong communities and great gameplay,” said John Linden, Mythical Games CEO. “Pudgy Penguins is the only web3 project to truly go mainstream through their incredible retail partnerships with Walmart and Target and their rapidly growing social media following. We are excited to combine their efforts with a game that will be played by millions. Building this with Mythical Games on the Mythical Platform and Mythos Chain, already used by millions of consumers, is going to be a major driver to further push web3 with mainstream consumers.”

Luca Netz, CEO of Pudgy Penguins said: “When we decided to create a mobile-first AAA blockchain-based Pudgy Penguins game, working with Mythical Games is something that excited me. Our growth strategy that has reached millions, combined with Mythical Games’ experience and success with gaming, sets up this endeavor for success. We can’t wait to show the Pudgy Penguins community what’s in store and solicit their feedback as development ramps up.”

In the build-up to its release, Pudgy Penguins holders will be treated to exclusive content, sneak peeks of in-game footage and given the opportunity to help shape key aspects of the game’s development. The game is designed to appeal to the Pudgy Penguins community as well as the broader gaming market to further grow the Pudgy Penguins’ brand and ethos.

Ahead of the game's launch in 2025, interested players can join Pudgy Penguins Discord, and follow Pudgy Penguins (@pudgypenguins) and Mythical Games (@playmythical) Twitter/X accounts to stay updated on the upcoming game.

About Pudgy Penguins

Pudgy Penguins is dedicated to making Web3 accessible to everyone by creating innovative products that enable seamless onboarding. Their focus on community empowerment and building brand awareness has made them a leader in the Web3 space while also disrupting the traditional web2, retail sphere. They're committed to impacting the everyday consumer and shaping the future of Web3.

Learn more: https://www.pudgypenguins.com/

About Mythical Games

Acknowledged by Fast Company’s World Changing Ideas 2021 and recently Forbes’ Best Startup Employers (2024), Mythical Games is a next-generation game company creating world-class games and empowering players to take ownership of their in-game assets through the use of blockchain technology. The team has helped develop major franchises, including Call of Duty, Call of Duty Mobile, World of Warcraft, Diablo, Overwatch, Magic: The Gathering, EA Madden, Harry Potter Hogwarts Mystery, Marvel Strike Force, Modern Warfare 3, and Skylanders.

The Mythical Marketplace, the first in-game blockchain Marketplace on iOS and Android, provides gamers with ownership and control over the purchase and sale of digital assets, while the Mythical Platform protects gamers that may be new to blockchain through a custodial wallet for their digital items.

Mythical Games is one of the 22 founding member companies of the Mythos Foundation (http://mythos.foundation) utilizing the Mythos Chain as its blockchain and Mythos’ MYTH token as the utility token for the Mythical Marketplace.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nate Nesbitt
Head of Communications
nate.nesbitt@mythical.games

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 05:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure22.6.2024 00:00:00 EEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 23:58:00 EEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 23:30:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 23:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye